Email Alerts IR Contacts RSS News Feed Press Releases All News By Year: 2019 2018 2017 2016 2015 2014 Oct 13, 2016 • 7:05 AM EDT Matinas BioPharma to Present at the 2nd Annual Dawson James Securities Growth Stock Conference Sep 28, 2016 • 7:00 AM EDT Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203 Sep 13, 2016 • 7:05 AM EDT Matinas BioPharma Completes Private Placement of $8.0 Million Sep 7, 2016 • 7:05 AM EDT Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA Sep 6, 2016 • 7:05 AM EDT Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016 Jul 13, 2016 • 7:00 AM EDT Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016 Jun 22, 2016 • 7:05 AM EDT Matinas BioPharma Receives Issuance of Key U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology Jun 20, 2016 • 7:35 AM EDT Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016 Jun 8, 2016 • 7:00 AM EDT Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016 Mar 31, 2016 • 7:05 AM EDT Matinas BioPharma Reports 2015 Financial Results and Provides Business Update << Previous 1... 5 6 7 8 9 10 11 12 13 14 ...16 Next >> Show All
Oct 13, 2016 • 7:05 AM EDT Matinas BioPharma to Present at the 2nd Annual Dawson James Securities Growth Stock Conference
Sep 28, 2016 • 7:00 AM EDT Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203
Sep 7, 2016 • 7:05 AM EDT Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA
Sep 6, 2016 • 7:05 AM EDT Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016
Jul 13, 2016 • 7:00 AM EDT Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016
Jun 22, 2016 • 7:05 AM EDT Matinas BioPharma Receives Issuance of Key U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Jun 20, 2016 • 7:35 AM EDT Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016
Jun 8, 2016 • 7:00 AM EDT Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016
Mar 31, 2016 • 7:05 AM EDT Matinas BioPharma Reports 2015 Financial Results and Provides Business Update